A tribunal has found a company that scrapes court databases broke privacy laws by failing to remove a litigant’s name after charges against her were dropped, saying the public nature of court lists doesn’t make republication a “free for all”.
A judge hearing a dispute over a lot in Victoria’s Merrifield Business Park has found that the Competition and Consumer Act’s bar on contracts that substantially lessen competition does not apply to a market in land.
A judge has vacated an upcoming trial date in a data scraping case against US-based CoreLogic to allow the analytics company more time to respond to a “weighty” report by a forensic accountant.
AMP is facing a new class action alleging certain superannuation fund members were hit with inflated premiums over a five-year period, after arguing a similar matter was “in search of a case” more than four years after being filed.
Roberts Co has appealed a decision which required it to pay the entirety of subcontractor Sharvain Facades $3.2 million payment claim, despite it being filed after hours on a Friday.
Investors in Till Payments have won discovery for a possible suit over $43 million in alleged losses suffered after it was sold for just $47 million following a $200 million capital raise, with a judge rejecting arguments that the bid amounted to a royal commission.
Stockbroking firm Ord Minnett has overturned a judgment finding it owed years of wages and other entitlements to a wealth adviser who was only paid in commissions.
Singer Katy Perry has asked the High Court to uphold the Full Court’s decision to knock out the ‘Katie Perry’ mark of an Australian fashion designer, as it gears up to hear an appeal raising issues about the construction of key provisions of the Trade Marks Act.
The owners of land acquired to build a Melbourne freeway have asked the High Court to overturn an “erroneous” appeals court decision which left them with $2 million for land worth over $30 million, saying the case raises important questions about the Land Acquisition and Compensation Act.
US biotech company Regeneron Pharmaceuticals has sued Sandoz, claiming it is threatening to infringe the patent for its Eylea biologic, used to treat macular degeneration and diabetic macular oedema.